HRP20200897T1 - Parenteralna formulacija esmolola - Google Patents
Parenteralna formulacija esmolola Download PDFInfo
- Publication number
- HRP20200897T1 HRP20200897T1 HRP20200897TT HRP20200897T HRP20200897T1 HR P20200897 T1 HRP20200897 T1 HR P20200897T1 HR P20200897T T HRP20200897T T HR P20200897TT HR P20200897 T HRP20200897 T HR P20200897T HR P20200897 T1 HRP20200897 T1 HR P20200897T1
- Authority
- HR
- Croatia
- Prior art keywords
- solution
- formulation
- esmolol hydrochloride
- use according
- ready
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167443 | 2012-05-10 | ||
| EP13721740.2A EP2846776B1 (en) | 2012-05-10 | 2013-05-08 | Parenteral esmolol formulation |
| PCT/EP2013/059594 WO2013167657A1 (en) | 2012-05-10 | 2013-05-08 | Parenteral esmolol formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200897T1 true HRP20200897T1 (hr) | 2020-11-27 |
Family
ID=48407551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200897TT HRP20200897T1 (hr) | 2012-05-10 | 2013-05-08 | Parenteralna formulacija esmolola |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20150087704A1 (OSRAM) |
| EP (1) | EP2846776B1 (OSRAM) |
| JP (1) | JP6220383B2 (OSRAM) |
| CN (1) | CN104379134A (OSRAM) |
| AU (1) | AU2013258031B2 (OSRAM) |
| BR (1) | BR112014027870B1 (OSRAM) |
| CA (1) | CA2872953C (OSRAM) |
| CL (1) | CL2014003028A1 (OSRAM) |
| DK (1) | DK2846776T3 (OSRAM) |
| EA (1) | EA032344B1 (OSRAM) |
| ES (1) | ES2794093T3 (OSRAM) |
| HR (1) | HRP20200897T1 (OSRAM) |
| HU (1) | HUE049314T2 (OSRAM) |
| IL (1) | IL235497A0 (OSRAM) |
| LT (1) | LT2846776T (OSRAM) |
| MA (1) | MA37500B1 (OSRAM) |
| MX (1) | MX374771B (OSRAM) |
| MY (1) | MY173900A (OSRAM) |
| NZ (1) | NZ701429A (OSRAM) |
| PH (1) | PH12014502494B1 (OSRAM) |
| PL (1) | PL2846776T3 (OSRAM) |
| PT (1) | PT2846776T (OSRAM) |
| SI (1) | SI2846776T1 (OSRAM) |
| TN (1) | TN2014000464A1 (OSRAM) |
| UA (1) | UA115333C2 (OSRAM) |
| WO (1) | WO2013167657A1 (OSRAM) |
| ZA (1) | ZA201408149B (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019122157A1 (en) * | 2017-12-21 | 2019-06-27 | Ipsol Ag | A lyophilisate comprising esmolol and adenosine for use in cardioplegia |
| CN111848420A (zh) * | 2020-07-22 | 2020-10-30 | 杭州煌森生物科技有限公司 | 一种盐酸艾司洛尔的新晶型及制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| TWI277414B (en) | 2001-01-12 | 2007-04-01 | Baxter Int | Esmolol formulation |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| WO2007026771A1 (ja) * | 2005-08-31 | 2007-03-08 | Ono Pharmaceutical Co., Ltd. | 点滴用注射剤 |
| US20080293814A1 (en) | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
| JP5623288B2 (ja) | 2007-12-21 | 2014-11-12 | エイオーピーオーファン ファーマスーティカルズ アクチエンゲゼルシャフトＡＯＰ Ｏｒｐｈａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 医薬組成物 |
| CN102106846A (zh) * | 2009-12-23 | 2011-06-29 | 南京海辰药业有限公司 | 左旋盐酸艾司洛尔药物组合物及其制备方法 |
-
2013
- 2013-05-08 JP JP2015510815A patent/JP6220383B2/ja active Active
- 2013-05-08 CN CN201380028099.XA patent/CN104379134A/zh active Pending
- 2013-05-08 SI SI201331732T patent/SI2846776T1/sl unknown
- 2013-05-08 HR HRP20200897TT patent/HRP20200897T1/hr unknown
- 2013-05-08 MX MX2014013556A patent/MX374771B/es active IP Right Grant
- 2013-05-08 WO PCT/EP2013/059594 patent/WO2013167657A1/en not_active Ceased
- 2013-05-08 LT LTEP13721740.2T patent/LT2846776T/lt unknown
- 2013-05-08 CA CA2872953A patent/CA2872953C/en active Active
- 2013-05-08 EA EA201491841A patent/EA032344B1/ru not_active IP Right Cessation
- 2013-05-08 UA UAA201413014A patent/UA115333C2/uk unknown
- 2013-05-08 DK DK13721740.2T patent/DK2846776T3/da active
- 2013-05-08 PT PT137217402T patent/PT2846776T/pt unknown
- 2013-05-08 US US14/398,312 patent/US20150087704A1/en not_active Abandoned
- 2013-05-08 NZ NZ701429A patent/NZ701429A/en unknown
- 2013-05-08 EP EP13721740.2A patent/EP2846776B1/en active Active
- 2013-05-08 PL PL13721740T patent/PL2846776T3/pl unknown
- 2013-05-08 ES ES13721740T patent/ES2794093T3/es active Active
- 2013-05-08 AU AU2013258031A patent/AU2013258031B2/en active Active
- 2013-05-08 HU HUE13721740A patent/HUE049314T2/hu unknown
- 2013-05-08 BR BR112014027870-9A patent/BR112014027870B1/pt active IP Right Grant
- 2013-05-08 MY MYPI2014703249A patent/MY173900A/en unknown
-
2014
- 2014-10-31 TN TN2014000464A patent/TN2014000464A1/fr unknown
- 2014-11-04 IL IL235497A patent/IL235497A0/en active IP Right Grant
- 2014-11-05 MA MA37500A patent/MA37500B1/fr unknown
- 2014-11-07 CL CL2014003028A patent/CL2014003028A1/es unknown
- 2014-11-07 PH PH12014502494A patent/PH12014502494B1/en unknown
- 2014-11-07 ZA ZA2014/08149A patent/ZA201408149B/en unknown
-
2017
- 2017-07-28 US US15/663,645 patent/US20170326095A1/en not_active Abandoned
-
2022
- 2022-01-24 US US17/582,945 patent/US11963940B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Combining ECMO with IABP for the treatment of critically Ill adult heart failure patients | |
| HRP20220470T1 (hr) | Uporaba landiolol hidroklorida u dugotrajnom liječenju tahiaritmija | |
| RU2367477C1 (ru) | Способ лечения хронической ишемии нижних конечностей | |
| Petrov | An electrocardiographic sine wave in hyperkalemia | |
| CN103393715B (zh) | 钠钾镁钙葡萄糖注射液及其制备方法 | |
| HRP20200897T1 (hr) | Parenteralna formulacija esmolola | |
| CN115919824B (zh) | Am404在制备防治心肌缺血再灌注损伤药物中的应用 | |
| JP6629850B2 (ja) | 汎用心停止液（変種） | |
| JP2015520142A5 (OSRAM) | ||
| JP2016510040A5 (OSRAM) | ||
| CN103340863A (zh) | 烟酰胺在制备治疗糖尿病伤口愈合药物中的应用 | |
| CN108815171A (zh) | 25-羟基胆固醇在制备治疗或预防心肌梗死的药物中的应用 | |
| CN204219095U (zh) | 单分支带环支架型人工血管 | |
| CN116785435B (zh) | Ep3受体拮抗剂l-798106在制备预防心肌缺血再灌注损伤药物中的应用 | |
| JP6153838B2 (ja) | 血管透過性抑制剤 | |
| CN105311040A (zh) | 一种含有果糖二磷酸钠的用于治疗循环系统疾病的新药物组合物针剂 | |
| CN105348171B (zh) | 一种治疗膝骨关节炎的药物组合物 | |
| CN112209834A (zh) | 一种有机亚硝酸根供体及其制备方法与医药用途 | |
| Han et al. | Valve replacement for valvular heart disease with giant left ventricle | |
| CN102028939B (zh) | 一种有效成分含有水蛭素的药物 | |
| CN102028938B (zh) | 一种具有活血化瘀作用的药物 | |
| RU2568911C1 (ru) | Средство для кардиоплегии (варианты) | |
| Peshin et al. | Effects of mephentermine and norepinephrine administration following thiopentone induced circulatory insufficiency in buffalo calves (Bubalus bubalis) | |
| CN107375310A (zh) | 延龄草苷在制备治疗心力衰竭药物中的用途 | |
| Cheung et al. | Temporary Mechanical Circulatory Support for Acute Right Ventricular Failure |